{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:16:43Z","timestamp":1788412603857,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006261","name":"Taif University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006261","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/014g1a453","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Patients with suspicious prostate mpMRI but negative baseline biopsy remain challenging to manage, as some are later diagnosed with clinically significant prostate cancer (csPCa). This study evaluated whether baseline whole-gland radiomic features from T2-weighted imaging and apparent diffusion coefficient (ADC) maps could predict subsequent csPCa detection. Methods: This retrospective radiomics sub-analysis of the MULTIPROS trial included men with suspicious baseline mpMRI findings (PI-RADS v2.0 categories 3\u20135) and no csPCa detected at baseline biopsy. The primary outcome was subsequent csPCa detection during follow-up, defined as ISUP Grade Group \u22652. Whole-gland prostate segmentation was performed on baseline T2-weighted images using a semi-automated approach with manual refinement, and the resulting T2-derived masks were applied to the spatially corresponding ADC maps. Radiomic features were extracted using PyRadiomics version 3.1.0a2 after standardised preprocessing. Feature robustness was assessed in a 20-patient reproducibility subset using intra- and inter-reader intraclass correlation coefficients, followed by correlation filtering and LASSO-based feature prioritisation. Radiomics-only, clinicoradiological-only, and clinicoradiological\u2013radiomic logistic regression models were evaluated using stratified five-fold cross-validation. Results: T2-based modelling included 151 patients, of whom 36\/151 (23.8%) had subsequent csPCa detected; the median time to csPCa detection or last follow-up was 64 months. ADC analyses included 144 patients, of whom 34\/144 (23.6%) had subsequent csPCa detected. The T2 clinicoradiological\u2013radiomic model achieved a mean AUC of 0.696 \u00b1 0.060, compared with 0.713 \u00b1 0.072 for the T2 clinicoradiological-only model and 0.456 \u00b1 0.091 for the T2 radiomics-only model. In the ADC-available cohort, ADC radiomics-only, ADC clinicoradiological\u2013radiomic, and combined T2 + ADC clinicoradiological\u2013radiomic models achieved mean AUCs of 0.684 \u00b1 0.052, 0.635 \u00b1 0.157, and 0.663 \u00b1 0.106, respectively. Calibration was imperfect, with deviations at higher predicted probabilities and overprediction in the highest predicted-risk bin. Conclusions: Baseline whole-gland MRI radiomics showed limited and inconsistent predictive value for subsequent csPCa detection after negative biopsy and did not demonstrate consistent incremental improvement over clinicoradiological predictors. These findings are exploratory and hypothesis-generating, and external validation is required before clinical use.<\/jats:p>","DOI":"10.3390\/cancers18172823","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"2823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Whole-Gland MRI Radiomics for Risk Stratification After Suspicious mpMRI and Negative Biopsy: A MULTIPROS Sub-Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Wafa D.","family":"Aloufi","sequence":"first","affiliation":[{"name":"Division of Imaging Sciences and Technology, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK"},{"name":"Department of Radiological Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szewczyk-Bieda","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8362-2432","authenticated-orcid":false,"given":"Asma","family":"Aloufi","sequence":"additional","affiliation":[{"name":"Department of Computer Science, College of Computers and Information Technology, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wei","sequence":"additional","affiliation":[{"name":"Division of Imaging Sciences and Technology, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-9701","authenticated-orcid":false,"given":"Luigi","family":"Manfredi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"European Association of Urology (2026, June 10). EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/diagnostic-evaluation."},{"key":"ref_3","unstructured":"National Institute for Health and Care Excellence (2026, June 10). Prostate Cancer: Diagnosis and Management. NICE Guideline NG131. Available online: https:\/\/www.nice.org.uk\/guidance\/ng131."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13603","DOI":"10.1038\/s41598-022-17260-6","article-title":"Follow-up of men with a PI-RADS 4\/5 lesion after negative MRI\/ultrasound fusion biopsy","volume":"12","author":"Kornienko","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_6","first-page":"149.e15","article-title":"An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer\u2014Preliminary experience","volume":"35","author":"Costa","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41391-024-00904-1","article-title":"Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS \u2265 3 lesions\u2014An EAU-YAU study enhancing prostate cancer detection","volume":"28","author":"Zattoni","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Antolin, A., Roson, N., Mast, R., Arce, J., Almodovar, R., Cortada, R., Maceda, A., Escobar, M., Trilla, E., and Morote, J. (2024). The role of radiomics in the prediction of clinically significant prostate cancer in the PI-RADS v2 and v2.1 era: A systematic review. Cancers, 16.","DOI":"10.3390\/cancers16172951"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7830909","DOI":"10.1155\/2021\/7830909","article-title":"Predicting the grade of prostate cancer based on a biparametric MRI radiomics signature","volume":"2021","author":"Zhang","year":"2021","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12672-024-00980-8","article-title":"Prediction of prostate cancer aggressiveness using magnetic resonance imaging radiomics: A dual-center study","volume":"15","author":"Pan","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Jing, G., Xing, P., Li, Z., Ma, X., Lu, H., Shao, C., Lu, Y., Lu, J., and Shen, F. (2022). Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.918830"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, T., Sun, L., Li, Q., Luo, X., Luo, M., Xie, H., and Wang, P. (2022). Development and validation of a radiomics nomogram for predicting clinically significant prostate cancer in PI-RADS 3 lesions. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.825429"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chaddad, A., Kucharczyk, M.J., and Niazi, T. (2018). Multimodal radiomic features for the predicting Gleason score of prostate cancer. Cancers, 10.","DOI":"10.3390\/cancers10080249"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s13063-019-3746-0","article-title":"A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer: MULTIPROS study protocol","volume":"20","author":"Wei","year":"2019","journal-title":"Trials"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e221428","DOI":"10.1148\/radiol.221428","article-title":"Multicenter randomized trial assessing MRI and image-guided biopsy for suspected prostate cancer: The MULTIPROS study","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging\u2014Reporting and Data System: 2015, Version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13244-023-01415-8","article-title":"CheckList for EvaluAtion of Radiomics research (CLEAR): A step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII","volume":"14","author":"Kocak","year":"2023","journal-title":"Insights Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The Image Biomarker Standardization Initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2022.07.025","article-title":"Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric magnetic resonance imaging (Prostate Imaging Reporting and Data System\/Likert 3\u20135) and negative initial biopsy. A mini systematic review","volume":"82","author":"Grivas","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13244-024-01783-9","article-title":"Optimizing radiomics for prostate cancer diagnosis: Feature selection strategies, machine learning classifiers, and MRI sequences","volume":"15","author":"Mylona","year":"2024","journal-title":"Insights Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jia, Y., Quan, S., Ren, J., Wu, H., Liu, A., Gao, Y., Hao, F., Yang, Z., Zhang, T., and Hu, H. (2022). MRI radiomics predicts progression-free survival in prostate cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.974257"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dominguez, I., Rios-Ibacache, O., Caprile, P., Gonzalez, J., San Francisco, I.F., and Besa, C. (2023). MRI-based surrogate imaging markers of aggressiveness in prostate cancer: Development of a machine learning model based on radiomic features. Diagnostics, 13.","DOI":"10.3390\/diagnostics13172779"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3390\/curroncol30020157","article-title":"Radiomic machine-learning analysis of multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: New combination of textural and clinical features","volume":"30","author":"Prata","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jin, P., Shen, J., Yang, L., Zhang, J., Shen, A., Bao, J., and Wang, X. (2023). Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: A retrospective multi-center study. BMC Med. Imaging, 23.","DOI":"10.1186\/s12880-023-01002-9"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Castillo, T.J.M., Starmans, M.P.A., Arif, M., Niessen, W.J., Klein, S., Bangma, C.H., Schoots, I.G., and Veenland, J.F. (2021). A multi-center, multi-vendor study to evaluate the generalizability of a radiomics model for classifying prostate cancer: High grade vs. low grade. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020369"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.21037\/qims.2019.12.06","article-title":"Radiomics prediction model for the improved diagnosis of clinically significant prostate cancer on biparametric MRI","volume":"10","author":"Li","year":"2020","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1038\/s41598-019-45766-z","article-title":"Repeatability of multiparametric prostate MRI radiomics features","volume":"9","author":"Schwier","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1038\/s41598-019-41344-5","article-title":"Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial","volume":"9","author":"Peerlings","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1148\/rg.2016150030","article-title":"Benign conditions that mimic prostate carcinoma: MR imaging features with histopathologic correlation","volume":"36","author":"Kitzing","year":"2016","journal-title":"Radiographics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"Fedorov","year":"2017","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1148\/radiol.2021202553","article-title":"The biological meaning of radiomic features","volume":"298","author":"Tomaszewski","year":"2021","journal-title":"Radiology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:38:53Z","timestamp":1788410333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":33,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172823"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172823","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}